Domenic Ciarico

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Par Sterile Products LLC engages in the development, manufacturing, and distribution of generic pharmaceuticals. Its products include adrenalin injection, adrenalin chloride solution, aplisol, argatroban injection, brevital sodium, buprenorphine HCL injection, CIII, colistimethate for injection, USP, coly-mycin m, dantrium IV, dantrium capsules, delestrogen, dexmedetomidine HCI, injection, ethacrynate sodium for injection, USP, fluphenazine decanoate injection, USP, ketalar, pitocin, tigan, triostat, vasostrict, and zoledronic acid injection. The company was founded in 2007 and is headquartered in Chestnut Ridge, NY.